Encyclopedia

GLOW Blend

GLOW Blend combines BPC-157, GHK-Cu, and TB-500 in a product marketed for tissue repair. No human trial validates the combination, its components rest on animal and preclinical data, and neither the blend nor its parts hold FDA approval for human use. Educational only, not medical advice.

Start free →Dose tools

Category	Healing / Recovery
Regulatory status	Not FDA-approved as a blend or as individual components for any human indication.

Mechanism

A combination product marketed for tissue repair: BPC-157 (a synthetic peptide derived from a gastric protein) is reported to promote angiogenesis and tendon/ligament healing, GHK-Cu (a copper tripeptide) supports collagen synthesis and wound remodeling, and TB-500 (a thymosin beta-4 fragment) is reported to promote cell migration and angiogenesis. The blend has no validated combined mechanism in humans.

Half-life

Not established for the blend; varies by component. BPC-157 half-life is poorly characterized in humans (limited human data); GHK-Cu and TB-500 human pharmacokinetics are also not well established. Treat all values as uncertain.

Regulatory status

Not FDA-approved as a blend or as individual components for any human indication. Sold as a research chemical. BPC-157 and TB-500 are not approved drugs and have been flagged by FDA; TB-500 (thymosin beta-4) is prohibited by WADA. Compounding of BPC-157 has been restricted by FDA (placed in category 2 of the 503A bulks review). GHK-Cu is used cosmetically but not approved as an injectable drug.

Safety

Sterility and product-purity risks are significant for unregulated injectables. Component-specific human safety data are limited; reported effects are largely anecdotal. Copper-containing peptides carry theoretical risk of copper accumulation with overuse. No long-term human safety data for the combination.

Evidence

Largely anecdotal for the blend; individual components have mostly animal/preclinical data with very limited human trials.

Sources

Hsieh MJ, et al. Pro-angiogenic BPC157 and VEGFR2 activation. J Mol Med. 2017;95(3):323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/
Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. Int J Mol Sci. 2018;19(7):1987. https://pubmed.ncbi.nlm.nih.gov/29986520/
Maquart FX, et al. GHK-Cu stimulation of connective tissue in rat wounds. J Clin Invest. 1993;92(5):2368-2376. https://pubmed.ncbi.nlm.nih.gov/8227353/

PepWise is an informational and educational tracking tool, not medical advice and not a medical device. GLOW Blend may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.